Poxel S.A. (PXXLF)
| Previous Close | 6.70 |
| Open | 6.70 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 6.70 - 6.70 |
| 52 Week Range | 6.03 - 11.25 |
| Volume | |
| Avg. Volume | 2 |
| Market Cap | 168.074M |
| Beta (5Y Monthly) | 1.56 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.38 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Poxel Announces the Formation of its Scientific Advisory Board for Rare Metabolic Diseases
LYON, France, December 06, 2021--POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced the formation of its Scientific Advisory Board (SAB) for rare metabolic diseases. The new SAB will initially focus on supporting Poxel's X-linked adrenoleukodystrophy (ALD) program.
- Business Wire
Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in November
LYON, France, November 03, 2021--POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced its participation at upcoming investor and scientific conferences in November 2021.
- Business Wire
Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2021
LYON, France, October 20, 2021--POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today provided a corporate update and announced its cash position and revenue for the third quarter and the nine months ended September 30, 2021.
